Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality

This parallel-group, randomized, triple-blind trial assessed the onset, magnitude and duration of antidepressant effect of two IV ketamine infusions (0.5 mg/kg each) compared with placebo in patients with treatment-resistant major depressive disorder with suicidal risk.

Primary outcomes include antidepressant response timing and change in suicidal ideation; safety monitoring included adverse events and vital signs. Actual enrollment recorded as 36 at Assiut University, Egypt.